Istodax

Istodax Uses, Dosage, Side Effects, Food Interaction and all others data.

Istodax is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated.

Trade Name Istodax
Availability Prescription only
Generic Romidepsin
Romidepsin Other Names Romidepsin, Romidepsina, Romidepsine, Romidepsinum
Related Drugs bexarotene, methoxsalen, Targretin, vorinostat, Folotyn, belinostat, pralatrexate, Targretin Gel, Istodax
Weight 10mg, 5mg/ml,
Type Intravenous powder for injection, intravenous solution
Formula C24H36N4O6S2
Weight Average: 540.69
Monoisotopic: 540.207627243
Protein binding

Highly protein bound in plasma (92%-94%)

Groups Approved, Investigational
Therapeutic Class
Manufacturer
Available Country Australia, Canada, United States,
Last Updated: September 19, 2023 at 7:00 am
Istodax
Istodax

Uses

Istodax is a histone deacetylase (HDAC) inhibitor used to treat cutaneous and peripheral T-cell lymphoma.

For the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated.

Istodax is also used to associated treatment for these conditions: Refractory peripheral cutaneous T-cell lymphoma

How Istodax works

Istodax is a prodrug, where it becomes active once taken up into the cell. The active metabolite has a free thiol group, which interacts with zinc ions in the active site of class 1 and 2 HDAC enzymes, resulting in inhibition of its enzymatic activity. Certain tumors have over expressed HDACs and downregulated/mutated histone acetyltransferases. This imbalance of HDAC relative to histone acetyltransferase can lead to a decrease in regulatory genes, ensuing tumorigenesis. Inhibition of HDAC may restore normal gene expression in cancer cells and result in cell cycle arrest and apoptosis.

Toxicity

Risk factor D in pregnancy. It is not known if romidepsin is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother. The majority of patients receiving romidepsin experience nausea, vomiting, and anorexia.

Food Interaction

  • Avoid grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum concentration of romidepsin.
  • Avoid St. John's Wort. This herb induces CYP3A4 metabolism, which may reduce serum levels of romidepsin.

Volume of Distribution

44.5L

Elimination Route

Istodax exhibited linear pharmacokinetics at standard doses.

Half Life

Approximately 3 hours

Clearance

8.4L/h

Innovators Monograph

You find simplified version here Istodax

*** Taking medicines without doctor's advice can cause long-term problems.
Share